Rare Disease Drug Extends Lives in Ovarian Cancer Patients by Four Months
A groundbreaking study has discovered that a medication typically prescribed for a rare disorder could significantly extend the lives of women battling a specific form of ovarian cancer. The research, published in The Lancet and presented at the SGO 2026 annual meeting on women's cancer, offers new hope for patients with platinum-resistant ovarian cancer.
Promising Results with Relacorilant
Women diagnosed with platinum-resistant ovarian cancer, where the disease progresses within six months of platinum-based chemotherapy, often face a grim prognosis, with an average survival of only about one year post-diagnosis. However, this new study involving 381 patients found that those receiving relacorilant—a pill already used for Cushing's syndrome and other cancers—alongside standard treatment lived an average of four months longer than those on usual care alone.
Specifically, women given relacorilant survived for an average of 16 months, compared to 11.9 months for those receiving standard care. The researchers noted that patients taking relacorilant were 35 per cent less likely to die from any cause during the study period.
The authors stated: "These outcomes—a 35 per cent reduction of the risk of death from any cause and a median overall survival improvement of 4.1 months—position relacorilant plus nab-paclitaxel as a new standard treatment option for patients with platinum-resistant ovarian cancer."
Immunotherapy Also Shows Survival Benefits
In a separate but related study published in the same journal and presented at the SGO 2026 meeting, researchers explored the potential of immunotherapy in treating platinum-resistant ovarian cancer. Immunotherapy works by stimulating the body's immune system to target and destroy cancer cells.
The study examined data from 643 women and found that patients who took pembrolizumab, an immunotherapy drug, along with usual care, lived for an average of 17.7 months. In contrast, those receiving standard care alone survived for an average of 14 months.
The research team concluded: "These findings support this regimen as a new standard of care for platinum-resistant ovarian cancer patients."
Implications for Future Treatment
These studies highlight a significant advancement in the management of platinum-resistant ovarian cancer, a condition that has historically had limited treatment options. The use of relacorilant, a repurposed drug, and immunotherapy like pembrolizumab could transform clinical practices and improve survival rates.
Further research is needed to confirm these results and explore potential side effects, but the initial data suggests a promising shift towards more effective, personalised treatment strategies for ovarian cancer patients.
